Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ES2B-C001
- Development stage
- Phase 1
- Lead developer
- ExpreS2ion Biotechnologies
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ES2B-C001 is a first-in-class therapeutic vaccine candidate designed to treat cancers that overexpress the human epidermal growth factor receptor 2 (HER2), with an initial focus on HER2-positive breast cancer. It is based on a virus-like particle (VLP) platform displaying the extracellular domain of HER2. The vaccine aims to induce a strong and durable polyclonal antibody response against HER2 by breaking immune tolerance and stimulating both humoral and cellular immunity. Preclinical studies have shown that ES2B-C001 can effectively inhibit tumor growth and metastasis in mouse models of HER2-positive breast cancer, including tumors resistant to trastuzumab. The drug is currently being evaluated in a first-in-human phase I clinical trial for safety, tolerability, immunogenicity, and preliminary antitumor activity in patients with metastatic HER2-expressing breast cancer[5][4][3].
- Other names
- ES2B C001ES-2B C001ES 2B C001HER2-cVLPHER-2-cVLPHER 2-cVLP
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ES2B-C001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ES2B-C001.